Olipudase alfa (acid sphingomyelinase deficiency) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Olipudase alfa (acid sphingomyelinase deficiency) – Benefit assessment according to §35a Social Code Book V

   published on

   03.08.2026

   Document type

   PDF document, 218 kB, DE, not accessible

   Download file : Extract of dossier assessment (PDF document, 218 kB, DE, not accessible)
2. Dossier assessment

   Olipudase alfa (acid sphingomyelinase deficiency) – Benefit assessment according to §35a Social Code Book V

   published on

   03.08.2026

   Document type

   PDF document, 1 MB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A26-48

   Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Project details

Project no.

A26-48

Commission

Commission awarded on 04.05.2026 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Digestion, metabolism and hormones

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-48

Connected Projects

1. Dossier assessment

   Olipudase alfa (ASMD) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

   Project no.

   G22-33

   Last updated

   02.01.2023

   Status: Commission completed